Click here to visit Company website
Cleveland BioLabs, Inc. is a biotechnology focused on developing biodefense, tissue protection and cancer treatment drugs based on concept of modulation of cell death for therapeutic benefit. CBLI's pipeline includes products from two primary families of compounds: protectans and curaxins. It is developing protectans as drug candidates that protect healthy tissues from acute stresses, such as , chemotherapy and ischemia. Curaxins are being developed as anticancer agents that could act as mono-therapy drugs or in combination with other existing anticancer therapies.